Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

NCT04251065 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
8
Enrollment
OTHER
Sponsor class

Stopped The enrolment was prematurely terminated after the planned monitoring of the first 5 patients because of an unacceptable level of relevant toxicities, according to statistical stopping rules and the DSMB recommendation.

Conditions

Interventions

Sponsor

Fondazione Italiana Linfomi - ETS